Kizoo leitet Finanzierungsrunde bei Reservoir Neuroscience zur Wiederherstellung der Gesundheit des alternden Gehirns

Aaron Friedman and Vlad Senatorov

Reservoir Neuroscience gab heute den Abschluss einer Finanzierungsrunde in Höhe von 4 Millionen Dollar bekannt, um die Entwicklung neuer Therapien für altersbedingte Neurodegeneration zu unterstützen. Reservoir wird die Mittel für die Entwicklung einer neuen Klasse von Wirkstoffen verwenden, die die Blutgefäße des Gehirns wiederherstellen sollen, um das alternde Gehirn zu verjüngen. Die Finanzierungsrunde wurde von Kizoo Technology Capital angeführt, einem führenden Investor im Bereich der Rejuvenation-Biotechnologie, der sich auf Start-ups mit Fokus auf der Umkehrung altersbedingter Schäden auf zellulärer und molekularer Ebene konzentriert. Weitere Investoren sind die Bestandsinvestoren R42 Fund und Healthspan Ventures.


Save the date: Rejuvenation Startup Summit: May, 10-11 in Berlin

Rejuvenation Startup Summit 2024

The Forever Healthy Foundation is pleased to announce the second edition of the Rejuvenation Startup Summit, following the inaugural Rejuvenation Startup Summit in 2022 with more than 400 participants from over 30 countries. It will take place on 10-11 May 2024 in Berlin.

The Rejuvenation Startup Summit is the world’s largest in-person gathering of longevity startups. It brings together startups, members of the longevity venture capital / investor ecosystem, and researchers interested in starting or joining a startup – all with the goal of accelerating the development of the rejuvenation biotech industry.


Kizoo portfolio company and Harvard spin-off CELLVIE closes $5.5M of additional funding to accelerate the development of Therapeutic Mitochondria Transplantation as a new treatment modality


Cellvie Inc., a leader in Therapeutic Mitochondria Transplantation (TMT), an approach developed at Harvard Medical School, closes a $5.5 Million financing to get Series A-ready by the end of 2023.

$5.5M financing led by Taiho Ventures LLC, with participation of existing investors, including the Series Seed lead, Kizoo Technology Capital.


Kizoo invests in Rejuvenation Startup MoglingBio


Berlin/Ulm, Germany – MoglingBio, a privately held biotech company, announces today that it has successfully completed its first seed investment round. Sole investor is venture capital firm Kizoo Technology Capital, a rejuvenation biotech investor focused on startups reversing age-related damage on a cellular and molecular level.


Rejuvenation Startup Summit premieres October, 14-15, 2022 in Berlin

Rejuvenation Startup Summit

The Forever Healthy Foundation is pleased to announce the world’s first Rejuvenation Startup Summit will be held October 14-15, 2022 in Berlin.

The Rejuvenation Startup Summit is a vibrant networking event for rejuvenation startups, longevity investors, and translational researchers, and aims to accelerate the development of the rejuvenation biotech industry.

Startups will be able to connect with investors in the longevity space, present their approach, and get them interested in their work. Investors can meet the most promising rejuvenation startups from all over the world and get in touch with them straight away. Researchers with a startup itch can learn how to successfully break out of the lab and found or join a rejuvenation startup.

The summit brings together all those working on therapies that aim to vastly extend the healthy human lifespan. In addition to an exciting range of keynotes speeches, presentations, and panels, the summit features an all-day startup forum for easy networking. Starting midday on Friday and finishing off on Saturday night with a big party, it offers ample opportunity to connect, learn and network with the most relevant players in the field.

The Rejuvenation Startup Summit is not only open to startups, investors, and translational scientists – all interested members of the broader longevity movement, scientists from related fields, aspiring students, and the general media are also welcome.

Learn more at:


Kizoo Portfolio Company Elastrin Therapeutics Inc. closes $10M Funding Round

Matthias Breugelmans and Naren Vyavahare
Dr. Breugelmanns and Prof. Dr. Vyavahare

Greenville, SC, U.S. – Elastrin Therapeutics Inc., a privately held biotechnology company leveraging a platform to develop therapeutics that render calcified tissue and organs supple again, today announced the closing of a $10 million funding round led by Kizoo Technology Capital, a leading early-stage investor in breakthrough rejuvenation technologies. Other investors in the round include Starbloom Capital and SC Launch. Elastrin Therapeutics was founded in 2018 as a spin-out from Clemson University, where the technology was first developed over a 20-year period.


Kizoo Portfolio Company Revel Pharmaceuticals Announces $8.4M Seed to Develop Repairing-Based Approaches to Reversing Aging

Aaron Cravens Portrait

San Francisco, CA, U.S. – Revel Pharmaceuticals, a longevity therapeutics company developing enzymes to repair damage from aging, announced today that it has raised $8.4M in Seed financing. The oversubscribed round was led by Kizoo Technology Capital, a leading early-stage investor in breakthrough rejuvenation technologies, and Starbloom Capital with participation from Tubus LLC. The funds will support Revel as it advances its repair-based enzyme therapy pipeline towards the clinic.


Kizoo Portfolio Company Staffbase Raises $115M at $1.1B Valuation to Achieve Global Leadership in Employee Communications Management

Banner Employee Communication Management

Chemnitz / Munich / New York – March 15, 2022 – Kizoo Portfolio Company Staffbase, a leading provider of employee communications management solutions, today announced a $115M (€106M) Series E financing round led by General Atlantic, a leading global growth equity firm. Staffbase will leverage the new funds to help scale internationally and strengthen its global leadership in the internal communications space. Existing investor Insight Partners also participated in the round.


Kizoo portfolio company LIfT BioSciences secures its largest financing to date with a further £5m

Hands forming a heart

London, UK ­– Kizoo portfolio company Biotech LIfT BioSciences today announced its largest financing round to date with a further £5m investment into the company in its mission to develop the first curative and affordable cell therapy for all solid tumours. The round was led by new investor Starbloom Capital with additional participation by Jonathan Milner, a leading biotech ‘super-angel’ investor and earlier stage investor in LIfT, Kizoo Technology Ventures, a leading early-stage investor in breakthrough rejuvenation technologies and Downing Ventures, a leading London-based investor.